Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 13/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.44 |
| ▸ | SMO | Q99835 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590691 | 0.88 | NR3C1 (0.66) | NR3C1SMOPGR | |
| SCHEMBL9913433 | 0.80 | TRPA1 (0.40) | NR3C1CYP11B1CYP11B2 | |
| SCHEMBL28769263 | 0.77 | NR3C1 (0.62) | NR3C1CYP11B1CYP11B2 | |
| SCHEMBL27704145 | 0.77 | NR3C1 (0.58) | NR3C1CYP11B1CYP11B2 | |
| SCHEMBL16300043 | 0.76 | NR3C1 (0.48) | NR3C1CYP11B1CYP11B2SMOPGR | |
| SCHEMBL27724842 | 0.75 | NR3C1 (0.53) | NR3C1CYP11B1CYP11B2PGR | |
| SCHEMBL4719472 | 0.75 | CYP11B1 (0.60) | NR3C1CYP11B1CYP11B2 | |
| SCHEMBL22199134 | 0.73 | NR3C1 (0.57) | NR3C1CYP11B1CYP11B2SMOPGR | |
| SCHEMBL27704147 | 0.72 | NR3C1 (0.52) | NR3C1CYP11B1CYP11B2SMO | |
| SCHEMBL27724578 | 0.72 | NR3C1 (0.52) | NR3C1CYP11B1CYP11B2SMOPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198311-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100075961-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075961-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NR0B1, NFKB2 | NR3C1 5/4885CYP11B1 69/4885CYP11B2 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.